Clinical trials: Narcolepsy Type 1
- Condition Narcolepsy Type 1
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Narcolepsy Type 1, Narcolepsy Type 2
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year.
- Trial name
- HYPNOS (NCT07299097)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 402 people
- Sponsor
- Takeda
Healthy Volunteers, Narcolepsy Type 1
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
The purpose of this study is to determine whether portable devices can provide measurements at home similar to those taken in the clinic, in particular in participant with NT1, and to investigate night-to-night changes in sleep…
- Trial name
- NCT04445129
- Testing
- Portable EEG Device, Portable ECG Device, Accelerometry
- Where
- 13 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Takeda
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time.
- Trial name
- NCT07363720
- Testing
- TAK-861
- Where
- 25 sites in United States, France and 5 more
- Volunteers
- 98 people
- Sponsor
- Takeda
Narcolepsy Type 1
A Study of TAK-861 in Participants With Narcolepsy Type 1
The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy.
- Trial name
- NCT05687903
- Testing
- TAK-861
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 112 people
- Sponsor
- Takeda
Narcolepsy Type 1
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
The main aim of this study is to learn how effective TAK-861 (oveporexton) is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment.
- Trial name
- NCT06470828
- Testing
- Oveporexton
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 168 people
- Sponsor
- Takeda
Narcolepsy Type 1
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
- Trial name
- NCT05816382
- Testing
- TAK-861
- Where
- 52 sites in United States, Australia and 10 more
- Volunteers
- 500 people
- Sponsor
- Takeda